2021 ASCO Virtual Direct™ Highlights


 

2021 ASCO Highlights on Leukemias: Ponatinib in CML, Blinatumomab + Ponatinib in Ph+ ALL, KTE-X19 in R/R B-cell ALL, Acalabrutinib vs. Ibrutinib in CLL, Enasidenib in IDH2-Mutated MDS

0 views
August 19, 2021
Comments 0
Login to view comments. Click here to Login